Shih-Ping Liu
Overview
Explore the profile of Shih-Ping Liu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
176
Citations
1616
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Yau Y, Lin S, Chang C, Chen P, Chen Y, Liu S, et al.
JBI Evid Implement
. 2025 Mar;
PMID: 40066710
Introduction: Oral hygiene is crucial in palliative care, as it directly affects patient comfort and quality of life. Aim: This study aimed to enhance oral hygiene practices in hospice wards...
2.
Ho C, Fan C, Chu Y, Liu S, Cheng P
Tissue Cell
. 2025 Feb;
94:102794.
PMID: 39970775
Bladder cancer is the most common type of urinary tumor. Current research has focused on alternative therapies that protect the bladder. Some studies suggested that cancer can be treated by...
3.
Huang Y, Liu S, Muo C, Lai C, Chang C
J Cachexia Sarcopenia Muscle
. 2024 Oct;
15(6):2684-2692.
PMID: 39351998
Background: The risk of sarcopenia in older adults with chronic kidney disease (CKD) not yet on dialysis is controversial. The aims of this study were to investigate the association among...
4.
Wang C, Lin G, Fu R, Huang Y, Chen S, Lin S, et al.
Cell Death Discov
. 2024 Sep;
10(1):407.
PMID: 39285205
Stem cells have the potential to replace damaged or defective cells and assist in the development of treatments for neurodegenerative diseases, including Parkinson's disease (PD) and Alzheimer's disease. iPS cells...
5.
Lin S, Chang Y, Lee W, Chiang C, Liu S, Lee H, et al.
Adv Sci (Weinh)
. 2024 Jul;
11(36):e2404882.
PMID: 39049677
The limited therapeutic strategies available for stroke leave many patients disabled for life. This study assessed the potential of programmed death-ligand 1 (PD-L1) and hepatocyte growth factor (HGF)-engineered mesenchymal stem...
6.
Lin S, Lee W, Liu S, Chang Y, Jeng L, Shyu W
Mol Neurobiol
. 2023 Nov;
61(7):3819-3835.
PMID: 38030932
Although tissue plasminogen activator (t-PA) and endovascular thrombectomy are well-established treatments for acute ischemic stroke, over half of patients with stroke remain disabled for a long time. Thus, a significant...
7.
Hong J, Kuo M, Cheng Y, Lu Y, Huang C, Liu S, et al.
World J Mens Health
. 2023 Oct;
42(3):587-599.
PMID: 37853534
Purpose: Active surveillance (AS) is one of the management options for patients with low-risk and select intermediate-risk prostate cancer (PC). However, factors predicting disease reclassification and conversion to active treatment...
8.
Huang H, Chen C, Chang K, Lee M, Lee C, Chao Y, et al.
J Transl Med
. 2023 Oct;
21(1):714.
PMID: 37821919
Purpose: Currently, there are no accurate markers for predicting potentially lethal prostate cancer (PC) before biopsy. This study aimed to develop urine tests to predict clinically significant PC (sPC) in...
9.
Wang C, Huang Y, Shyu W, Jeng L, Liu S
Regen Ther
. 2023 Sep;
24:443-450.
PMID: 37753387
The iPS cells were discovered in 2006. With their ability to differentiate into cells of all three germ layers, iPS cells have great potential for clinical applications. Oct4, Sox2, c-Myc,...
10.
Fu R, Hong S, Tsai C, Liu S, Chiu S, Wu M, et al.
Cells
. 2023 Mar;
12(6).
PMID: 36980235
Glioblastoma (GBM) is a primary brain tumor of unknown etiology. It is extremely aggressive, incurable and has a short average survival time for patients. Therefore, understanding the precise molecular mechanisms...